EMA recommends non-renewal of authorisation of multiple myeloma medicine Blenrep

View source ↗

Summary

EMA recommends non-renewal of the marketing authorisation for Blenrep (belantamab mafodotin) for multiple myeloma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Blenrep (belantamab mafodotin)